MarketPeel
Insider Trading Intelligence
CL

Clarus Ventures III Gp, L.p.

PRAX
10% OWNER · PRAXIS PRECISION MEDICINES, INC. · CIK 0001620148
FILING MIX · LIFETIME50%/50%
BUYS
11
SELLS
11
TOTAL VALUE
$3.40M
COMPANIES
2
ACTIVE SINCE
Jul 2020
HOLDINGS NOW
4,894,109
AVG SELL PX
TRADE KIND
SHOWING 22 / 22
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Clarus Ventures III Gp, L.p., measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+6.89%+2.77%+4.13%+4.13%
14d1+100.00%+33.07%+3.62%+29.45%+29.45%
30d1+100.00%+32.69%+8.46%+24.23%+24.23%
60d1+100.00%+27.85%+2.76%+25.09%+25.09%
90d1+100.00%+38.80%+6.10%+32.70%+32.70%
180d1+100.00%+41.74%+20.68%+21.07%+21.07%
1y1+100.00%+21.46%+38.68%-17.22%-17.22%
2y1+0.00%-70.71%+30.15%-100.86%-100.86%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PRAX · 4,894,109 shares · as of May 12, 2021
01,898,5273,797,0555,695,5827,594,1092021SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2021
2021
FLOW · 11 buys / 11 sellsCOVERAGE · 4 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PRAX
PRAXIS PRECISION MEDICINES, INC.
SALE
2,700,0004,894,109May 12, 2021May 14, 2021View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
SALE
352,7340Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
SALE
1,410,4770Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
SALE
559,2080Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
SALE
1,941,7480Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
PURCHASE
3,446,7114,147,645Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
PURCHASE
261,3187,429,277Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
SALE
7,375,7990Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
PURCHASE
659,1167,167,959Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
PURCHASE
164,8327,594,109Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
SALE
5,052,8520Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
PURCHASE
2,361,1986,508,843Oct 20, 2020Oct 22, 2020View →
PRAX
PRAXIS PRECISION MEDICINES, INC.
PURCHASE
907,378907,378Oct 20, 2020Oct 22, 2020View →
ANNX
ANNEXON, INC.
PURCHASE
200,000$17.00$3.40M2,730,635Jul 28, 2020Jul 30, 2020View →
ANNX
ANNEXON, INC.
SALE
5,666,6670Jul 28, 2020Jul 30, 2020View →
ANNX
ANNEXON, INC.
PURCHASE
643,208643,208Jul 28, 2020Jul 30, 2020View →
ANNX
ANNEXON, INC.
PURCHASE
239,4332,530,635Jul 28, 2020Jul 30, 2020View →
ANNX
ANNEXON, INC.
SALE
2,109,4070Jul 28, 2020Jul 30, 2020View →
ANNX
ANNEXON, INC.
SALE
8,370,6850Jul 28, 2020Jul 30, 2020View →
ANNX
ANNEXON, INC.
PURCHASE
697,8602,291,202Jul 28, 2020Jul 30, 2020View →
ANNX
ANNEXON, INC.
PURCHASE
950,1341,593,342Jul 28, 2020Jul 30, 2020View →
ANNX
ANNEXON, INC.
SALE
6,148,1470Jul 28, 2020Jul 30, 2020View →
Other insiders · PRAX
Loading peer insiders…
About this filer
CIK 0001620148
ROLE
10% Owner
PRIMARY
PRAX
COMPANIES
2
ACTIVE SINCE
Jul 2020
MARKETPEEL · /INSIDER/0001620148DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback